CP2 is overexpressed in many cancers, such as hepatocellular carcinoma (Yoo et al. 2010), pancreatic cancer (Yuedi et al. 2017) and colorectal cancer (Jiang et al. 2014), and mostly serves as a pro-oncogene (Kotarba et al. 2018). Here, TFCP2 is linked to cancer.